[A16-48] Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V
Last updated 05.01.2017
Project no.:
A16-48
Commission:
Commission awarded on 13.07.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-73 | Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48 | Commission completed |
| A20-86 | Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-26 | Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-01-05 A G-BA decision was published.